Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + SBRT in locally advanced HNSCC
NCT05861557Phase 2Unknown
- Sponsor
- Tianjin Medical University General Hospital
- Start
- May 2023
- Primary completion
- May 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Tianjin Medical University General Hospital. Primary endpoint: Major Pathological Response at 6 months. Status: unknown.
02
Drugs
toripalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05861557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05861557.